Docket No.: PF-0637 USN

his correspondence is being deposited with the United States Postal Service as first class mail in an envelope top: Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Printed:

Lyza Fimuliar

OCT

FIN THE UNITED STATES PATENT AND TRADEMARK OFFICE CENTER 1600/2900 I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop: Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

In re Application of:

Title:

NEURON-ASSOCIATED PROTEINS

Serial No.:

09/857,826

Filing Date:

June 07, 2001

Examiner:

Turner, S.

Group Art Unit:

1647

Mail Stop: Non-Fee Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

1

115182

09/857,826

Docket No.: PF-0637 USN

- HogNo 37,027

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE CORPORATION

James M. Verna, Ph.D.

Reg. No. 33,287

Direct Dial Telephone: (650) 845 -5415

Customer No.: 27904 3160 Porter Drive

Palo Alto, California 94304 Phone: (650) 855-0555 Fax: (650) 845-4166

Date: 09 October 2003

Sheet 1 of 1

· · · · · · · · · · · · · · · · · · ·							21100	<u> </u>
U.S. Department of Commerce, Patent and Trademark Office					Atty Docket No.		Serial No.	
					PF-0637 USN		09/857,826	
OIPE LIST OF REFERENCES CITED BY APPLICANTS					Applicants Dr			
To the second se					Tang et al.			
OCT 1 4 2003 (Use several sheets if necessary)					Filing Date OCT From			
2					June 7, 2001 CENT 1647			
RADEMI			U.S.	Patent Documents			"A TOUS, Z	<u> </u>
*Examiner		Document					Filing D	ate
Initial		Number	Date	Name	Class	Subclass	If Appro	
		/						
Foreign Patent Documents								
	<u> </u>						Translation	
		Document	Date	Country	Class	Subclass	Yes	No
	L							
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
	1	Yoshikawa, T., et al., (Direct Submission), NCBI Accession No. AF009426 (GI 2271472), 17 February 1998.						
	2	Xu, L., et al., (Direct Submission), NCBI Accession No. AF224278 (GI 9255808), 18 July 2000.						
	3	Jolliffe, C., et al., (Direct Submission), NCBI Accession No. AF220208 (GI 12004973), 5 March 2001.						
	4	Sehra, H., (Direct Submission), NCBI Accession No. AL035541 (GI 11546043), 24 February 2001.						
	5	Xu, L. L., et al., "PMEPA1, an Androgen-regulated NEDD4-binding Protein, Exhibits Cell Growth Inhibitory Function and Decreased Expression during Prostate Cancer Progression", Cancer Research 63:4299-4304 (2003)						
	6	Brunschwig, E. B., et al., "PMEPA1, a Transforming Growth Factor-β-induced Marker of Terminal Colonocyte Differentiation Whose Expression Is Maintained in Primary and Metastatic Colon Cancer", Cancer Research 63:1568-1575 (2003)						
	7	Xu, L. L., et al., "A Novel Androgen-Regulated Gene, PMEPA1, Located on Chromosome 20q13 Exhibits High/Level Expression in Prostate", Genomics 66:257-263 (2000)						
	8	Jolliffe, C., et al., "Identification of multiple proteins expressed in murine embryos as binding partners for the WW domains of the ubiquitin- protein ligase Nedd4", Biochem. J. 351:557-565 (2000)						
Examiner			Date Considered					
*EXAMINER: MPEP 609; D	raw li	al if reference.ne through cit	ation if not	, whether or not c	itation d not co		rmance wit Include co	